Citation Impact
1 from Science/Nature 63 standout
Citing Papers
Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide
2024 Standout
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
2024 Standout
Works of B-Y. Ryoo being referenced
LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)
2022 Standout
Author Peers
| Author | Oncology | PRM | Hepatology | Surgery | Last Decade | Papers | Cites |
|---|---|---|---|---|---|---|---|
| B-Y. Ryoo | 310 | 327 | 149 | 165 | 35 | 571 | |
| Bo Kong | 2 | 8 | 57 | 749 | |||
| Chia‐I Ko | 29 | 14 | 4 | 18 | 13 | 346 | |
| Markéta Trnková | 126 | 18 | 2 | 77 | 18 | 300 | |
| Gusti M. Zeiner | 6 | 78 | 9 | 14 | 669 | ||
| Carol A. Friesen | 11 | 73 | 5 | 94 | 49 | 1.8k |
All Works
Loading papers...